Soleus Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
Other funds holding XENE
Soleus Capital Management's XENE Position: Q3 2026 in Review
Soleus Capital Management reduced its Xenon Pharmaceuticals (XENE) stake by 23% in Q3 2026, selling an estimated $3.68M and leaving 205,000 shares worth $7.62M. The position accounts for 0.27% of the portfolio, ranked #62.
Soleus Capital Management first reported a position in XENE in Q4 2019 and has held it in 20 quarters since. The position peaked at $17M in Q1 2026. 288 funds tracked by Wall St. Rank hold XENE as of Q3 2026.
- Soleus Capital Management held 205,000 shares of Xenon Pharmaceuticals worth $7.62M as of Q3 2026.
- Soleus Capital Management sold 62,000 Xenon Pharmaceuticals shares in Q3 2026, an estimated $3.68M.
- Xenon Pharmaceuticals made up 0.27% of Soleus Capital Management's portfolio in Q3 2026, its #62 holding.
- Soleus Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2019 and has held it in 20 quarters since.
- Soleus Capital Management's Xenon Pharmaceuticals position peaked at $17M in Q1 2026.
- 288 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.
Based on Soleus Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.